Drug Profile
ALD 401
Alternative Names: ALD401; ALDHbrLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Aldagen
- Class Anti-ischaemics; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 05 May 2014 Discontinued - Phase-II for Stroke in USA (Intracarotid)
- 31 Mar 2014 ALD 401 is available for licensing as of 31 Mar 2014. http://www.cytomedix.com/
- 06 Jan 2014 Cytomedix completes enrolment in the phase III RECOVER-Stroke trial for Stroke in USA (NCT01273337)